Everolimus

Everolimus is an orally administered targeted medicine belonging to the mammalian target of rapamycin (mTOR) inhibitor class. It is a derivative of the macrolide compound sirolimus and acts by binding to the intracellular protein FKBP-12, forming a complex that inhibits mTOR signaling, particularly mTOR complex 1. This pathway regulates cell growth, proliferation, metabolism, and blood-vessel development, so its inhibition can reduce the growth and progression of certain tumors. Everolimus is available as tablets and, for selected tuberous sclerosis complex indications, as tablets for oral suspension. In oncology, it is used in selected patients with hormone receptor-positive, HER2-negative advanced breast cancer, advanced renal cell carcinoma, and progressive neuroendocrine tumors. It is also used for certain manifestations of tuberous sclerosis complex, including renal angiomyolipoma, subependymal giant cell astrocytoma, and associated partial-onset seizures. Because everolimus affects both tumor biology and immune and metabolic pathways, treatment requires appropriate patient selection and monitoring for adverse effects such as stomatitis, infections, metabolic abnormalities, pneumonitis, and myelosuppression.

Everolimus was developed as an oral rapamycin derivative for targeted inhibition of the mTOR pathway. Its oncology development began in the early 2000s, and the United States Food and Drug Administration granted the first U.S. oncology approval for advanced renal cell carcinoma on March 30, 2009. The European Medicines Agency granted EU-wide marketing authorisation for Afinitor on August 3, 2009. Subsequent FDA approvals expanded its use to subependymal giant cell astrocytoma associated with tuberous sclerosis complex in 2010, progressive pancreatic neuroendocrine tumors in 2011, renal angiomyolipoma associated with tuberous sclerosis complex in 2012, gastrointestinal and lung neuroendocrine tumors in 2016, and adjunctive treatment of tuberous sclerosis complex-associated partial-onset seizures in 2018. Key clinical development programs included RECORD-1 in renal cell carcinoma, RADIANT-3 and RADIANT-4 in neuroendocrine tumors, and BOLERO-2 in hormone receptor-positive advanced breast cancer.

Everolimus is used for several approved indications depending on the formulation and regulatory jurisdiction. In oncology, it is indicated for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following a non-steroidal aromatase inhibitor; for progressive, unresectable or metastatic neuroendocrine tumors of pancreatic origin; for progressive, unresectable or metastatic well-differentiated non-functional neuroendocrine tumors of gastrointestinal or lung origin; and for advanced renal cell carcinoma following progression after VEGF-targeted therapy. Everolimus is also indicated for certain tuberous sclerosis complex-associated renal angiomyolipomas, subependymal giant cell astrocytomas that require treatment but cannot be curatively resected, and associated partial-onset seizures. The breast cancer indication uses everolimus in combination with exemestane, whereas several other indications use everolimus as a single targeted therapy.

Everolimus is administered orally, with dosing determined by the indication, formulation, patient age, hepatic function, concomitant medicines, and tolerability. For advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, advanced renal cell carcinoma, and tuberous sclerosis complex-associated renal angiomyolipoma, the standard adult dose of everolimus tablets is 10 mg once daily, taken consistently either with food or without food. Treatment is generally continued while clinical benefit persists and toxicity remains acceptable. For tuberous sclerosis complex-associated subependymal giant cell astrocytoma and partial-onset seizures, dosing is individualized and may require therapeutic drug monitoring and dose titration according to blood everolimus concentrations. Dose interruption or reduction may be required for clinically significant toxicity, hepatic impairment, or important drug interactions. Tablets should be administered according to the prescribed formulation instructions and should not routinely be crushed or chewed.

Common adverse effects of everolimus include stomatitis or mouth ulcers, rash, diarrhea, nausea, reduced appetite, fatigue, weakness, headache, weight loss, infections, cough, swelling of the extremities, anemia and other blood-count abnormalities. Metabolic effects such as increased blood glucose, increased cholesterol or triglycerides, and electrolyte abnormalities may occur. Taste disturbance and nosebleeds can also occur. In patients receiving everolimus for cancer, stomatitis, infections, rash, diarrhea, fatigue, pneumonitis, anemia and metabolic abnormalities are among the clinically relevant adverse effects reported in studies and product information. Side effects vary according to indication, dose, patient characteristics, and concomitant treatment, and many can be managed through supportive care, dose interruption, or dose modification under medical supervision.

Important risks associated with everolimus include non-infectious pneumonitis, serious or opportunistic infections, severe hypersensitivity reactions, stomatitis, renal impairment or renal failure, impaired wound healing, myelosuppression, and significant metabolic abnormalities such as hyperglycemia and dyslipidemia. Everolimus can reduce immune responses and may increase susceptibility to infection, while vaccination responses may also be reduced during treatment. Angioedema has been reported particularly with concomitant use of angiotensin-converting enzyme inhibitors. Treatment may need to be interrupted, dose-reduced, or discontinued when serious or persistent toxicity develops. Patients should be assessed promptly for new or worsening respiratory symptoms because non-infectious pneumonitis can require treatment modification. Everolimus can also cause fetal harm when administered during pregnancy and requires appropriate reproductive counselling.

Everolimus requires careful consideration in patients with hepatic impairment, active or recurrent infections, diabetes, dyslipidemia, pulmonary disease, renal impairment, or conditions associated with impaired wound healing. Baseline and periodic monitoring commonly includes blood counts, renal and hepatic function, glucose, and lipid levels, with additional assessments guided by the indication and clinical circumstances. Live vaccines should generally be avoided during treatment because everolimus can suppress immune responses. Everolimus is substantially metabolized by CYP3A4 and is a substrate of P-glycoprotein, so strong CYP3A4 or P-glycoprotein inhibitors or inducers can significantly alter drug exposure and may require avoidance or dose adjustment. Concomitant angiotensin-converting enzyme inhibitors can increase the risk of angioedema. Careful review of all prescription medicines, non-prescription medicines, and supplements is therefore recommended before and during therapy.

Before starting everolimus, clinicians should confirm the indication, review prior and concomitant therapies, assess infection risk, and obtain appropriate baseline blood counts, renal and hepatic function, glucose, and lipid measurements. Patients receiving everolimus for tuberous sclerosis complex-associated subependymal giant cell astrocytoma or partial-onset seizures may require therapeutic drug monitoring and individualized dose titration. Oral administration should be consistent in relation to food, and adherence should be reinforced because treatment is generally continuous rather than given in short chemotherapy cycles. Patients should be counselled to report mouth ulcers, fever or other signs of infection, new cough or breathing difficulty, unexplained bleeding, marked swelling, or other significant symptoms promptly. Pharmacists should review potential CYP3A4 and P-glycoprotein interactions and check formulation-specific administration requirements. Coordination between oncology, neurology, nephrology, surgery, and other relevant specialties may be appropriate when everolimus is being used for complex tuberous sclerosis or cancer-related treatment plans.